
ADC Therapeutics SA: updates and filings
Price
$1.33
November 20, 2026Market cap $169M
What Ploutos Investor adds for ADC Therapeutics SA
Part of Ploutos Investor, €9.99 a month
- The full history: 8 fiscal years, from 2018
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 22% since Nov 9, 2026, when the 10-Q these figures come from was filed ($1.67 then, $1.30 on Nov 19, 2026). The figures date from before that move.10-Q
- The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 9, 2026next Feb 9, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
June 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 19, 2026FilingFormEFFECT
- Nov 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 10, 2026Shelf registration for future offeringsFormS-3
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 9, 2026Results of operationsForm8-K
- Nov 4, 2026Results of operations, Regulation FD disclosure, other material eventsForm8-K
- Nov 3, 2026FORM S-4FormS-4
- Oct 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Oct 13, 2026Material agreement entered, results of operations, unregistered sale of sharesForm8-K
- Aug 14, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 13, 2026Shares registered for employeesFormS-8
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Results of operations, Regulation FD disclosureForm8-K
- Jul 27, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Jul 2, 2026Officer or director changeForm8-K
- Jun 24, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 3, 2026Regulation FD disclosure, other material eventsForm8-K
- Jun 2, 2026Shareholder voteForm8-K
- May 4, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 4, 2026Results of operationsForm8-K
- Apr 24, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 20, 2026Additional annual meeting materialFormDEFA14A
- Apr 20, 2026Annual meeting proxy statementFormDEF 14A
- Apr 10, 2026Preliminary proxy statementFormPRE 14A
- Apr 6, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 19, 2026 | EFFECT | Filing | Document |
| Nov 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 10, 2026 | S-3 | Shelf registration for future offerings | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 9, 2026 | 8-K | Results of operations | Document |
| Nov 4, 2026 | 8-K | Results of operations, Regulation FD disclosure, other material events | Document |
| Nov 3, 2026 | S-4 | FORM S-4 | Document |
| Oct 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Oct 13, 2026 | 8-K | Material agreement entered, results of operations, unregistered sale of shares | Document |
| Aug 14, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 13, 2026 | S-8 | Shares registered for employees | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | 8-K | Results of operations, Regulation FD disclosure | Document |
| Jul 27, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Jul 2, 2026 | 8-K | Officer or director change | Document |
| Jun 24, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 3, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Jun 2, 2026 | 8-K | Shareholder vote | Document |
| May 4, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 4, 2026 | 8-K | Results of operations | Document |
| Apr 24, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 20, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 20, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 10, 2026 | PRE 14A | Preliminary proxy statement | Document |
| Apr 6, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 27, 2019.
The full analysis
What do ADC Therapeutics SA's filings show?
The filings are where every one of ADC Therapeutics SA's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.